CCK: The Complete Biology of the Body's Primary Gut Satiety Hormone

This comprehensive CCK review covers its dual role as a satiety signal (reducing meal size) and digestive hormone (gallbladder contraction, pancreatic secretion), with CCK-A receptors as validated obesity drug targets.

Chandra, Rashmi et al.·Current opinion in endocrinology·2007·Strong EvidenceReview
RPEP-01213ReviewStrong Evidence2007RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Strong Evidence
Sample
Not reported

What This Study Found

CCK operates as both the primary gut satiety signal (reducing meal size through vagal afferent and brain CCK-A receptors) and a digestive coordinator (gallbladder contraction, pancreatic secretion) — the most comprehensively characterized gut hormone.

Key Numbers

How They Did This

review study on neuropeptides, weight-loss.

Why This Research Matters

Relevant for neuropeptides, weight-loss, gut-healing.

The Bigger Picture

Advances peptide research.

What This Study Doesn't Tell Us

See abstract.

Questions This Raises

  • ?Further research needed.
  • ?Clinical translation to evaluate.

Trust & Context

Key Stat:
Key finding CCK operates as both the primary gut satiety signal (reducing meal size through vagal afferent and brain CCK-A receptors) and a digestive coordinator
Evidence Grade:
strong evidence.
Study Age:
Published in 2007.
Original Title:
Cholecystokinin.
Published In:
Current opinion in endocrinology, diabetes, and obesity, 14(1), 63-7 (2007)
Database ID:
RPEP-01213

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

What was studied?

CCK: The Complete Biology of the Body's Primary Gut Satiety Hormone

What was found?

This comprehensive CCK review covers its dual role as a satiety signal (reducing meal size) and digestive hormone (gallbladder contraction, pancreatic secretion), with CCK-A receptors as validated obesity drug targets.

Read More on RethinkPeptides

Cite This Study

RPEP-01213·https://rethinkpeptides.com/research/RPEP-01213

APA

Chandra, Rashmi; Liddle, Rodger A. (2007). Cholecystokinin.. Current opinion in endocrinology, diabetes, and obesity, 14(1), 63-7.

MLA

Chandra, Rashmi, et al. "Cholecystokinin.." Current opinion in endocrinology, 2007.

RethinkPeptides

RethinkPeptides Research Database. "Cholecystokinin." RPEP-01213. Retrieved from https://rethinkpeptides.com/research/chandra-2007-cholecystokinin

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.